Testing OPB-201 cell therapy for recurrent endometrial cancer and platinum-resistant ovarian cancer

Who can take part

• Age ≥ 18 years of age at the time of signing the informed consent form
• Histologically confirmed diagnosis of endometrial cancer, epithelial ovarian, peritoneal, or fallopian tube cancer based on local histopathological findings
• Received at least 1 prior line of systemic chemotherapy including a platinum-based chemotherapy
• Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1/2 mutation
• Measurable disease
• Consent to provide archived tumor tissue sample
• ECOG performance status of 0 or 1
• Adequate organ function
• HLA-A *02:01 or HLA-A *02:02
• PRAME positive tumor

Who cannot take part

• Had an allogenic tissue/solid organ transplant
• Concurrent treatment with systemic high dose corticosteroids
• Unresolved acute effects of any prior therapy
• Uncontrolled bacterial, fungal, or viral infections
• Active infection requiring systemic therapy
• Bleeding or thrombotic disorders or at risk for severe hemorrhage
• Active autoimmune disease
• Women of child-bearing potential who are pregnant or breastfeeding
• Any form of primary immunodeficiency
• Other exclusions as stated in the protocol